Nature's Sunshine Products Inc

Nature's Sunshine Products Inc(NATR)の株式分析

$14.210

+0.296 (+2.08%)終値時点

Loading chart…
High
14.300
Open
14.020
VWAP
14.16
Vol
240.63K
Mkt Cap
281.51M
Low
13.980
Amount
3.41M
EV/EBITDA, TTM
7.70

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk.

AI analysis of Nature's Sunshine Products Inc (NATR)

hold

Nature's Sunshine Products Inc (NATR) is currently not a strong buy due to recent performance declines and earnings misses. The stock is trading at $14.21, down 32.24% year-to-date, and the RSI is at a low 29.336, indicating potential oversold conditions. However, the forward P/E ratio is a reasonable 12.6422, suggesting some value, but the recent downgrade in revenue guidance and insider selling (161.97% increase in selling activity) presents significant risks.

バリュエーション指標

The current forward P/E ratio for Nature's Sunshine Products Inc (NATR) is 12.64, compared to its 5-year average forward P/E of 12.88.

Forward P/E

Fair
5Y Average P/E
12.88
Current P/E
12.64
割高
58.40
割安
-32.64

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
6.43
Current EV/EBITDA
7.70
割高
9.09
割安
3.76

Forward P/S

Undervalued
5Y Average P/S
0.63
Current P/S
0.47
割高
0.77
割安
0.49

Alphio AI Price Scenarios for NATR

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NATR

$16.58

シナリオ価格

B

Base

Base · 50%NATR

$16.06

シナリオ価格

B

Bear

Bear · 25%NATR

$14.23

シナリオ価格

Whales holding NATR

S

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

+ HoldingNATR

-23.63%

3M Return

イベントタイムライン

2026-08-06 (ET)

18:30:00

Nature's Sunshine Appoints Ruth Perkins as CFO

2026-05-07 (ET)

17:50:00

Reiterates FY26 Revenue View of $500M-$515M

17:50:00

Company Reports Q1 Revenue of $122.9M

2026-04-30 (ET)

09:20:00

Nature's Sunshine Appoints John Hnanicek as CTO

2026-03-10 (ET)

16:30:00

Company Expects FY26 Adjusted EBITDA of $50M-$54M

ニュース

NATR FAQ — answered by Alphio AI

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk. It operates in the Consumer Non-Cyclicals sector (PHARMACEUTICAL PREPARATIONS industry).

Nature's Sunshine Products Inc (NATR) is currently not a strong buy due to recent performance declines and earnings misses. The stock is trading at $14.21, down 32.24% year-to-date, and the RSI is at a low 29.336, indicating potential oversold conditions. However, the forward P/E ratio is a reasonable 12.6422, suggesting some value, but the recent downgrade in revenue guidance and insider selling (161.97% increase in selling activity) presents significant risks.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める